864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED
INZUCCHI S, BHATT D, PITT B, SZAREK M, CANNON C, LEWIS J, RIDDLE M, KOSIBOROD M, CHERNEY D, DWYER J, SCIRICA B, BAILEY C, BANKS P, DIAZ R, RAY K, UDELL J, LOPES R, LEITER L, STEG P. 864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED. Diabetes 2022, 71 DOI: 10.2337/db22-864-p.Peer-Reviewed Original ResearchGlucose-lowering medicationsPre-specified subgroupsNovartis Pharmaceuticals CorporationGlaxoSmithKline plcDaiichi SankyoDual SGLT1Baseline A1CBaseline eGFRPfizer Inc.Bristol-Myers Squibb CompanyLexicon PharmaceuticalsOutcome trialsCSL BehringNovo NordiskNovartis AGAdvanced chronic kidney diseaseType 2 diabetes patientsEli LillyAmgen Inc.Lower baseline eGFROverall trial populationCKD stage 4Primary composite outcomeSpeakers bureauCardiovascular outcome trials